BIOA B — BioArctic AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK26.00bn
- SEK24.10bn
- SEK2.00bn
Brief: Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025
Brief: Bioarctic Receives European Substance Patent For Exidavnemab
Europe Research Roundup: Adyen, L'Oréal, Novo Nordisk
Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
Brief: Bioarctic - EC Refers Lecanemab Marketing Authorisation Decision To Appeal Committee
Brief: Bioarctic Says Eisai Simulates Leqembi Sales To Reach JPY 250-280 Bln In FY 2027
Brief: Bioarctic Receives Orphan Drug Designation For Exidavnemab In The US
Brief: Bioarctic - Therapeutic Goods Administration Decides Not To Register Lecanemab In Australia
Brief: Bioarctic Says Global License Agreement With Bristol Myers Squibb For Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance And Closing
Brief: BioArctic Says Sales Of Leqembi Reached EUR 200 Million In Eisai FY 2024
Brief: Bioarctic Proposes No Dividend For FY 2024
Brief: BioArctic Q4 Operating Profit SEK -53.5 Million
Brief: BioArctic Says Sales Of Leqembi Totaled 13.3 Bln Yen In Q4 2024
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Brief: Bioarctic Says FDA Accepts Biologics License Application For Subcutaneous Maintenance Dosing Of Leqembi In US
Brief: Bioarctic Announces Global License Agreement For Antibody Program
Brief: Bioarctic AB Says Leqembi Approved In Mexico
Brief: Leqembi Launched In South Korea
RBC ups BioArctic TP after CHMP's Alzheimer's drug recommendation